Tislelizumab after liver tumor radiation to reduce cancer return
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (hepatocellular carcinoma) confirmed by biopsy or specific scan findings, and you plan to get liver radiation
- Your cancer has not spread outside the liver (no extrahepatic spread or large suspicious lymph nodes on scans)
- Your overall health is good enough for treatment (performance status score 0–2) and you are age 18 or older
- Your liver and blood tests are within allowed limits (Child-Pugh class A or B7, and adequate blood counts and organ function)
- You must not have had certain past liver radiation types, prior immunotherapy, or a liver transplant
- You must be willing to follow birth control rules during treatment and for at least 6 months after the last dose (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving tislelizumab (an immunotherapy drug) at different infusion times after surgery can lower the chance of liver cancer coming back in people at high risk of recurrence.
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
This trial studies whether taking tislelizumab alone or with lenvatinib before surgery can shrink recurrent liver cancer and improve outcomes. It may help by treating the cancer earlier (before the tumor is removed).
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
Hear when a new Liver Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.